Company Overview
Artemis Medicare Services Limited engages in the management and operation of multi-specialty hospitals in India and internationally. The company provides medical and surgical intervention, and inpatient and outpatient services. It also offers billing and insurance, childcare, emotional and support program, full body checkup, international patient, medical interpreter and record, mind body medicine, nursing, nutrition, patient and family advisory, patient advocacy and portal, pre-admission testing, and smoking cessation program services, as well as home care services. Artemis Medicare Services Limited was incorporated in 2004 and is based in Gurugram, India.
Why Investors Should Care
Net profit has compounded at 26.6% per year over the last five years.
Revenue has grown at a 10.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.28.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹1,081.00 Cr (+15.4% YoY); net profit ₹104.00 Cr.
- Trailing 12 Months Year-on-year growth — revenue +15.4%, earnings +26.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.2%, profit CAGR 26.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.22% |
| 1 Year: | 15.37% |
Compounded Profit Growth
| 5 Years: | 26.56% |
| 1 Year: | 26.83% |
Stock Price Performance
| 1 Year: | +10.06% |
| 6 Months: | +2.75% |
| 3 Months: | +21.57% |
| 1 Month: | +4.96% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.2% over 5 years.
- Profit CAGR of 26.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195.00 Cr | 210.00 Cr | 225.00 Cr | 219.00 Cr | 225.00 Cr | 223.00 Cr | 241.00 Cr | 232.00 Cr | 240.00 Cr | 255.00 Cr | 275.00 Cr | 272.00 Cr | 279.00 Cr |
| Operating Expenses | 170.00 Cr | 182.00 Cr | 191.00 Cr | 186.00 Cr | 187.00 Cr | 187.00 Cr | 199.00 Cr | 195.00 Cr | 204.00 Cr | 214.00 Cr | 224.00 Cr | 228.00 Cr | 228.00 Cr |
| Operating Income | 17.00 Cr | 19.00 Cr | 24.00 Cr | 23.00 Cr | 27.00 Cr | 25.00 Cr | 31.00 Cr | 26.00 Cr | 24.00 Cr | 30.00 Cr | 39.00 Cr | 33.00 Cr | 39.00 Cr |
| EBITDA | 26.00 Cr | 28.00 Cr | 34.00 Cr | 33.00 Cr | 38.00 Cr | 36.00 Cr | 42.00 Cr | 37.00 Cr | 36.00 Cr | 41.00 Cr | 51.00 Cr | 45.00 Cr | 52.00 Cr |
| Interest Expense | 5.00 Cr | 7.00 Cr | 8.00 Cr | 8.00 Cr | 9.00 Cr | 8.00 Cr | 8.00 Cr | 8.00 Cr | 8.00 Cr | 7.00 Cr | 7.00 Cr | 7.00 Cr | 6.00 Cr |
| Pretax Income | 14.00 Cr | 13.00 Cr | 19.00 Cr | 16.00 Cr | 20.00 Cr | 22.00 Cr | 31.00 Cr | 27.00 Cr | 29.00 Cr | 30.00 Cr | 39.00 Cr | 30.00 Cr | 40.00 Cr |
| Tax Provision | 3.36 Cr | 3.38 Cr | 5.32 Cr | 4.64 Cr | 5.80 Cr | 5.28 Cr | 8.68 Cr | 6.21 Cr | 5.80 Cr | 8.70 Cr | 9.36 Cr | 7.50 Cr | 10.00 Cr |
| Net Income | 11.00 Cr | 10.00 Cr | 14.00 Cr | 12.00 Cr | 14.00 Cr | 17.00 Cr | 22.00 Cr | 21.00 Cr | 23.00 Cr | 21.00 Cr | 30.00 Cr | 22.00 Cr | 30.00 Cr |
| Diluted EPS | 0.79 | 0.72 | 1.00 | 0.85 | 1.04 | 1.22 | 1.62 | 1.50 | 1.67 | 1.53 | 2.16 | 1.41 | 1.90 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 547.00 Cr | 565.00 Cr | 408.00 Cr | 555.00 Cr | 737.00 Cr | 879.00 Cr | 937.00 Cr | 1,081.00 Cr |
| Operating Expenses | 481.00 Cr | 503.00 Cr | 373.00 Cr | 487.00 Cr | 643.00 Cr | 746.00 Cr | 785.00 Cr | 893.00 Cr |
| Operating Income | 46.00 Cr | 39.00 Cr | 13.00 Cr | 46.00 Cr | 63.00 Cr | 93.00 Cr | 107.00 Cr | 140.00 Cr |
| EBITDA | 66.00 Cr | 62.00 Cr | 35.00 Cr | 68.00 Cr | 94.00 Cr | 133.00 Cr | 152.00 Cr | 188.00 Cr |
| Interest Expense | 11.00 Cr | 13.00 Cr | 13.00 Cr | 12.00 Cr | 20.00 Cr | 31.00 Cr | 32.00 Cr | 28.00 Cr |
| Pretax Income | 37.00 Cr | 31.00 Cr | 8.00 Cr | 37.00 Cr | 51.00 Cr | 68.00 Cr | 108.00 Cr | 139.00 Cr |
| Tax Provision | 16.65 Cr | 11.16 Cr | 1.44 Cr | 5.92 Cr | 12.75 Cr | 19.04 Cr | 25.92 Cr | 34.75 Cr |
| Net Income | 20.00 Cr | 19.00 Cr | 6.00 Cr | 31.00 Cr | 38.00 Cr | 49.00 Cr | 82.00 Cr | 104.00 Cr |
| Diluted EPS | 0.97 | 1.49 | 0.49 | 2.40 | 2.88 | 3.62 | 6.00 | 6.55 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 554.00 Cr | 586.00 Cr | 600.00 Cr | 710.00 Cr | 905.00 Cr | 972.00 Cr | 1,357.00 Cr | 1,429.00 Cr |
| Total Equity | 293.00 Cr | 313.00 Cr | 320.00 Cr | 359.00 Cr | 403.00 Cr | 449.00 Cr | 838.00 Cr | 935.00 Cr |
| Total Debt | 114.00 Cr | 113.00 Cr | 147.00 Cr | 201.00 Cr | 286.00 Cr | 320.00 Cr | 290.00 Cr | 262.00 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 40.00 Cr | 56.00 Cr | 27.00 Cr | 60.00 Cr | 127.00 Cr | 109.00 Cr | 146.00 Cr | 132.00 Cr |
| Investing Cash Flow | -50.00 Cr | -26.00 Cr | -37.00 Cr | -107.00 Cr | -158.00 Cr | -88.00 Cr | -385.00 Cr | -90.00 Cr |
| Financing Cash Flow | 14.00 Cr | -27.00 Cr | 18.00 Cr | 44.00 Cr | 38.00 Cr | -29.00 Cr | 267.00 Cr | -50.00 Cr |
| Capital Expenditure | -57.00 Cr | -26.00 Cr | -31.00 Cr | -109.00 Cr | -145.00 Cr | -72.00 Cr | -91.00 Cr | -100.00 Cr |
| Free Cash Flow | -17.00 Cr | 30.00 Cr | -4.00 Cr | -49.00 Cr | -18.00 Cr | 37.00 Cr | 55.00 Cr | 32.00 Cr |
| Net Change in Cash | 5.00 Cr | 2.00 Cr | 8.00 Cr | -3.00 Cr | 7.00 Cr | -8.00 Cr | 27.00 Cr | -8.00 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | 8.4% | 6.9% | 3.2% | 8.3% | 8.5% | 10.6% | 11.4% | 13.0% |
| Net Margin % | 3.7% | 3.4% | 1.5% | 5.6% | 5.2% | 5.6% | 8.8% | 9.6% |
| ROE % | 6.8% | 6.1% | 1.9% | 8.6% | 9.4% | 10.9% | 9.8% | 11.1% |
| ROCE % | - | - | - | - | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARTEMISMED
Should You Buy Artemis Medicare Services Limited (NSE:ARTEMISMED) For Its Upcoming Dividend? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPSVlHWXlRcGtpc0RlZkRjWXIyMWtSUjNfQzFjcDA4X3VCZ3lwYWZ5cHF3WUxzVjAyM1V2N1RmM0YtOUY5eXZac1V0cVh0Y2F6NGpqUXNsVXBTN0xkblFuME5VLWhtZkZzRHpwdVJfQ1NCUXp4eTZNZW9naGdCQ0hHVWFwa0Q1X2pjZmZtSW…
Additional Considerations Required While Assessing Artemis Medicare Services' (NSE:ARTEMISMED) Strong Earnings - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNeDM1V3hIUkRxY1JiWjgtam94S282RGhHWWFCdkx2dFNhZ1M5QzVIXzlDb21JOFZaU1V2SHpxeEdSTWxXZ2swMTlKNFFRTWlqS05pbldsVGo3dE56V2RvcHhwVExqcDFXNkxtM1pJOUkwc0dsSVp6Ynp3SEVRZTRLT3JtYzNsanAtYnNzcX…
Should You Be Adding Artemis Medicare Services (NSE:ARTEMISMED) To Your Watchlist Today? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNUFh4VXNzTXJyaThtVlhYNnFOTG1nYW8zY2FMNjRJZERLV2ZYazk3UlZsSGlqMkVpenp5c1FOX0xxVE1sWVNjc0tjYS1JZ3lrZWVHWjBJS3hNUVdTNUhyTmZid2xHdlpPQ1JzZDFqOFJKMDNQOVoyeXh0dlBjTUN4WDNBU3JPajEzVnJ4Q3…
Artemis Medicare Services Ltd. Share Price Live Today - CNBC TV18
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPWHJ1MXh4WXMtdmVNS1prY3NPY1FXTTk5MnpKSHZGSzZLZDJadldXN1lBRHhVNlNtX2NCNTVxSjNLWmlJdWhqWWIzSWQyUGF2cll1eEE4dVo0ck9uTE1FeC1VNlA2U3BKTk1NeXRwcUExaXdmMTJNMG1kZVp6ZjM3OE1yRVdHcnZlSmFtVG…
ARTEMISMED Stock Price and Chart — NSE:ARTEMISMED - TradingView
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFB3NjREdEZIdS11TVFzU2wxRUwxdGRSYW8xS3JnQi1tWGxXb3h2Y1RHejNnLU52UmFIcmxfeXd4b3l5RE5vQ3NyQ0psVkUwZ2owejhDSWJ0VFdvRDV3aGNMQg?oc=5" target="_blank">ARTEMISMED Stock Price and Chart — NS…
Artemis Medicare Services (NSE:ARTEMISMED) surges 13% this week, taking five-year gains to 880% - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxQRjhpYzF3bnJRdDhDcVBDUDNNbmFHakhWZk1PY1YxN2IwdURtMmh2VjRfYjBJT0NTTmRhYUV6LWFLbnNfZWo5YVl0MmZ5ejlzMXVxSVQ2WFpxampLNDJNNzlRVzJoc0hrSXpIcm5ocmFIZjViMnplYnRSMk1MM0VraF9ZdFFoM3h5cUtjMU…
ARTEMISMED — Frequently Asked Questions
What is the current share price of Artemis Medicare Services Limited (ARTEMISMED)?
As of 2026-07-15 09:52 IST, Artemis Medicare Services Limited (ARTEMISMED) trades at ₹276.95 on NSE. Its 52-week range is ₹205.16 to ₹287.62.
What is the P/E ratio of ARTEMISMED?
ARTEMISMED trades at a trailing price-to-earnings (P/E) ratio of 42.28. Its price-to-book (P/B) ratio is 4.69.
What is the return on equity (ROE) of ARTEMISMED?
ARTEMISMED has a return on equity (ROE) of 11.12%.
Is ARTEMISMED a good stock to buy?
This page provides a data-driven analysis of Artemis Medicare Services Limited (ARTEMISMED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.